KPV 10mg

KPV (Lys-Pro-Val) 10mg is a synthetic tripeptide compound designed for research and laboratory use. Derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), KPV has been the subject of scientific investigation into anti-inflammatory signalling, immune modulation, and gastrointestinal mucosal biology. Each vial is manufactured to research-grade purity standards to ensure consistency and reliability in experimental settings. Ideal for qualified researchers and institutions studying melanocortin-derived peptides, NF-κB pathway modulation, and inflammatory bowel disease models. Store in a cool, dry place away from direct light. For research purposes only.

Specification Active Ingredient: KPV (Lys-Pro-Val tripeptide) Concentration: 10mg per vial Form: Lyophilized powder Purity: ≥95% (research grade) Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Intended Use: Laboratory and research applications only Not intended for human or veterinary use.

Molecular Formula: C₁₇H₃₁N₅O₅ Molecular Weight: 385.46 g/mol Tripeptide Sequence: Lys-Pro-Val Constituent Amino Acids: Lysine (L-Lys): C₆H₁₄N₂O₂ — Proline (L-Pro): C₅H₉NO₂ — Valine (L-Val): C₅H₁₁NO₂ Derivation: C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) Mechanism: Melanocortin receptor-mediated anti-inflammatory and immune-modulatory activity; NF-κB pathway inhibition Purity Analysis: ≥95% by HPLC

Storage Before Reconstitution: Store in original sealed vial at 2–8°C in a cool, dry place away from direct sunlight and moisture. Keep below 40% relative humidity. Shelf life: 24 months from manufacture date when stored as directed. Keep container tightly sealed between uses. Storage After Reconstitution: Once dissolved in sterile water or saline, refrigerate at 2–8°C immediately. Use within 7 days of reconstitution. Do not freeze reconstituted solutions. Discard any solution showing visible discoloration, cloudiness, or particulates. Use sterile technique throughout. For long-term storage beyond 12 months, −20°C freezer storage of the lyophilised powder is recommended. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. α-MSH and KPV: Anti-Inflammatory Activity of the C-Terminal Tripeptide
   Catania A, et al. (2004). The neuropeptide alpha-melanocyte-stimulating hormone in the control of inflammation. Pharmacological Reviews, 56(4), 569–611. https://doi.org/10.1124/pr.56.4.3
   Comprehensive review establishing KPV as the bioactive C-terminal tripeptide of α-MSH responsible for its anti-inflammatory properties, detailing MC1R and MC3R receptor interactions, NF-κB inhibition, and pro-inflammatory cytokine suppression — the foundational mechanistic reference for all KPV research.
2. KPV and NF-κB Pathway Inhibition
   Bhatt DL & Bhatt DL. (Referenced via): Brzoska T, et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 29(5), 581–602. https://doi.org/10.1210/er.2007-0027
   Detailed review of α-MSH-derived tripeptides including KPV, covering their molecular mechanisms of NF-κB inhibition, cytokine suppression (IL-1β, TNF-α, IL-6), and protective effects in inflammatory disease models — providing the key biochemical framework for KPV anti-inflammatory research.
3. KPV and Intestinal Inflammation: Colitis Models
   Kannengiesser K, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine experimental colitis. Inflammatory Bowel Diseases, 14(3), 324–331. https://doi.org/10.1002/ibd.20334
   Demonstrates KPV’s direct anti-inflammatory activity in murine DSS-induced colitis models, showing significant reduction in colonic inflammation scores, cytokine levels, and mucosal damage — establishing KPV as a research tool for gastrointestinal inflammatory pathway studies.
4. KPV Cellular Uptake and Intracellular Anti-Inflammatory Signalling
   Dalmasso G, et al. (2008). The peptide KPV mediates anti-inflammatory effects in the gut via α-MSH receptor-independent pathways. American Journal of Physiology – Gastrointestinal and Liver Physiology, 294(4), G1004–G1013. https://doi.org/10.1152/ajpgi.00021.2008
   Demonstrates that KPV exerts anti-inflammatory effects in intestinal epithelial cells via receptor-independent intracellular mechanisms, including direct inhibition of NF-κB and MAPK signalling pathways — providing critical mechanistic insight for researchers studying KPV’s mode of action at the cellular level.
5. KPV Nanoparticle Delivery and Mucosal Targeting Research
   Laroui H, et al. (2013). Fab’-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. Journal of Controlled Release, 186, 41–53. (See also: Laroui H, et al. (2010). Gastrointestinal delivery of anti-inflammatory nanoparticles. Journal of Controlled Release, 141(3), 384–391.) https://doi.org/10.1016/j.jconrel.2009.09.030
   Investigates KPV-loaded nanoparticle formulations for targeted gastrointestinal delivery, demonstrating enhanced mucosal uptake and anti-inflammatory efficacy in colitis models — relevant for researchers exploring KPV delivery mechanisms and gut-targeted peptide research applications.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.